Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.54 |
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | CCNH | P51946 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 6/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546292 | 0.94 | CCNT1 (0.56) | CCNT1CDK9CDK1CCNB1CCNA2 | |
| SCHEMBL2542008 | 0.91 | BTK (0.51) | CDK9CDK1CCNA2CDK2EGFR | |
| SCHEMBL2542426 | 0.91 | SYK (0.46) | CCNT1CDK9CDK1CCNB1CCNA2 | |
| SCHEMBL2543943 | 0.85 | FLT3 (0.51) | CCNT1CDK9CDK1CCNB1CCNA2 | |
| SCHEMBL2545785 | 0.85 | BTK (0.53) | CCNT1CDK9CDK1CCNB1CCNA2 | |
| SCHEMBL28784438 | 0.85 | CDK2 (0.45) | CCNT1CDK9CDK1CCNB1CCNA2 | |
| SCHEMBL2542034 | 0.83 | FLT3 (0.55) | CCNT1CDK9CDK1CCNB1CCNA2 | |
| SCHEMBL2540539 | 0.82 | CCNT1 (0.55) | CCNT1CDK9CDK1CCNB1CCNA2 | |
| SCHEMBL2546231 | 0.82 | MKNK1 (0.48) | CDK1CCNA2CDK2EGFRSYK | |
| SCHEMBL2541347 | 0.81 | ACVR1 (0.57) | CCNT1CDK9CDK1CDK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | claimed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | claimed |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | MAP3K20, MAP3K1, MAP3K2 | CCNT1 1213/4885CDK9 242/4885CDK1 129/4885 |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | NFKBIA, IRAK1, IRAK3 | CCNT1 3334/4885CDK9 763/4885CDK1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.